SCHEMBL6764764

SCHEMBL6764764

Nc1nccc(-c2cccc(O)c2)n1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 2/20 0.62
PRKACA P17612 2/20 0.62
AURKA O14965 2/20 0.62
ADORA2A P29274 1/20 0.62
HSP90AB1 P08238 1/20 0.56
PTK2 Q05397 1/20 0.56
HSD17B1 P14061 3/20 0.55
HSD17B2 P37059 3/20 0.55
KMO O15229 1/20 0.54
MAP4K4 O95819 1/20 0.52
PIK3CA P42336 2/20 0.52
PIK3CG P48736 2/20 0.51
ADORA1 P30542 1/20 0.51
PIK3CB P42338 1/20 0.51
HDAC6 Q9UBN7 1/20 0.51
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
PLK1 P53350 1/20 0.49
PDPK1 O15530 2/20 0.48
CDK2 P24941 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18014622 0.89 CDK5 (0.68) HSP90AA1PRKACAAURKAADORA2AHSP90AB1
SCHEMBL4708076 0.82 HSP90AA1 (0.67) HSP90AA1PRKACAAURKAADORA2AHSP90AB1
SCHEMBL4202167 0.81 HSP90AA1 (0.76) HSP90AA1PRKACAAURKAADORA2AHSP90AB1
SCHEMBL27115833 0.80 KMO (0.59) HSP90AA1PRKACAAURKAADORA2AHSP90AB1
SCHEMBL481304 0.79 PRKACA (0.62) HSP90AA1PRKACAAURKAADORA2AHSP90AB1
SCHEMBL5229810 0.79 HSP90AA1 (0.62) HSP90AA1PRKACAAURKAADORA2AHSP90AB1
SCHEMBL823885 0.79 HSD17B1 (0.55) HSD17B1HSD17B2KMOMAP4K4PIK3CA
SCHEMBL12821368 0.78 HSP90AA1 (0.66) HSP90AA1PRKACAAURKAADORA2AHSP90AB1
SCHEMBL316210 0.77 HSP90AA1 (1.00) HSP90AA1PRKACAAURKAADORA2AHSP90AB1
SCHEMBL30862097 0.77 HSD17B1 (0.66) HSD17B1HSD17B2MAP4K4MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040242633-A1 Beta3 adrenergic agonists EVERS BRITTA (DE) 2004-12-02 US disclosed
US-6730792-B2 PYRIDINE DERIVATIVES; ANTIDIABETIC, ANTICHOLESTEROL, AND ANTIINFLAMMATORY AGENTS; DECYCLIZATION, DEETHERIFICATION; OBESITY; RAISES HIGH DENSITY LIPOPROTEINS; LOWERS TRIGLYCERIDE LEVELS ELI LILLY AND COMPANY 2004-05-04 US disclosed
US-20030191156-A1 Beta3 adrenergic agonists JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT 2003-10-09 US disclosed
CN-1441800-A β3Adrenergic agonists LILLY CO ELI (US) 2003-09-10 CN disclosed
EP-1303509-A1 BETA3 ADRENERGIC AGONISTS ELI LILLY AND COMPANY (US) 2003-04-23 EP disclosed
WO-2002006276-A1 BETA3 ADRENERGIC AGONISTS ELI LILLY AND COMPANY (US) 2002-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030191156-A1 Beta3 adrenergic agonists ADRB3, ADRB1, ADRB2 HSP90AA1 1689/4885PRKACA 3845/4885AURKA 4786/4885
US-20040242633-A1 Beta3 adrenergic agonists ADRB3, ADRB1, ADRB2 HSP90AA1 1469/4885PRKACA 4100/4885AURKA 4780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.